Ann: Selected for oral presentation at ASH, page-3

Great to see progress SNT marching forward

From the Abstract

Patients are allowed to vary RUX dose during the study, and any pt that discontinues RUX will be allowed to continue treatment with PXS-5505 at the Investigator’s discretion. You know its safe when Trial Patients continue on Treatment outside of the parameters of the Trial NZT

Results:

As of 31 of July 2024, AOP completed planned enrollment with 15 pts enrolled and treated (median age 72 years [range 46-82]). Of the treated patients, 47% were male; 2 had post-ET MF, 7 post-PV MF, 6 PMF, 3 were high risk and the remainder were Int-2 risk. The median time since MF diagnosis was 58 months (range 6.5->120), with median MPN-SAF TSS of 22.5 (range, 10-52). Median duration of previous RUX therapy was 26 months (range, 3.5-74) and the median daily dose of RUX at study entry was 20mg (range 5 -40 mg) with 13 pts having a best response of stable disease as per IWG on RUX at BL. BL median spleen volume was 1353 cm³ (n=14). Median BL hemoglobin was 94 g/dL (range, 66 - 132 g/dL) and 11/15 had hemoglobin <100 g/dL at BL. Two pts were transfusion-dependent at enrollment; 40% of pts had platelet levels below 100x10⁹/L. Of the 11 patients with available BL mutation profile, 7 had a JAK2 V617F mutation and 6 had ≥1 high risk mutation (ASXL1, EZH2, SRSF2, IDH1/2, U2AF1).

Updated efficacy and safety data will be presented at the conference including 12-week data from all pts.

Conclusion:

The results from this trial using a novel combination of PXS-5505 and RUX will add to the existing safety profile of PXS-5505 and provide preliminary indicators of efficacy to help inform future investigations of PXS-5505 in pts with MF.

$$$$ Value is on its way to SNT ,,NZT